Vivus (VVUS.Q) jumps 47% after FDA approval of improved Pancreaze pancreatic medication

If you’ve had your eye off the biotech sector recently because it doesn’t directly involve gold or cannabis, you’re missing out on one of the better casinos out there. For the high risk, high reward investor, nothing is quite like the thrill of correctly picking when a long, drawn out, US Food and Drug Administration process of approving a new drug finally gets over the line.

Xphyto (XPHY.C) blowing the weed sector out of the water with true 2.0 plan

Xphyto (XPHY.C) is dominating the cannabis sector like Sean Kemp used to dominate the Seattle buffet scene. It’s a legit beast right now, jumping from fat new high to fat new high. We’ve sat with their team several times over the past year and on each occasion have been impressed with their plans, but perhaps the greatest plan they’ve executed has been achieved over the past month, when their share price has elevated from $1.00 to $1.85.